PDF) Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the
How I treat elderly patients with plasma cell dyscrasias
OUH - Group members
A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma - ScienceDirect
Plasma cell tumors
PDF) Health-Related Quality of Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma
Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant
Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies: JACC: CardioOncology State-of-the-Art Review - ScienceDirect
OUH - Oslo Myeloma Center
Oman Medical Journal-Archive
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial - ScienceDirect
Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation - Transplantation and Cellular Therapy, Official Publication of the American
/cms/asset/b6d321b3-1847-46ce-8
Baseline patient characteristics and PROs
Biomedicines, Free Full-Text
